Physician profile
Ashok Nath
NPI 1992951115
$13,262.53
in general payments reported to CMS, 2019-2025
35 companies · $1,010 in 2025
The $1,010 reported for 2025 was more than what 78% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $840 · 2020: $342 · 2021: $950 · 2022: $1,887 · 2023: $6,546 · 2024: $1,688 · 2025: $1,010.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,557 · Consulting Fee: $2,700 · Travel and Lodging: $1,962 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,557.14 |
| Consulting Fee | $2,700.00 |
| Travel and Lodging | $1,962.00 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $6,044.75 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,010.57 | 2020-2025 | Lokelma, Farxiga |
| Akebia Therapeutics INC | $792.12 | 2019-2025 | Vafseo, Auryxia |
| Vifor Pharma, INC. | $619.32 | 2019-2024 | Veltassa, Korsuva |
| Ardelyx, INC. | $549.17 | 2024-2025 | Ibsrela, Xphozah 30 Mg |
| Otsuka America Pharmaceutical, INC. | $508.62 | 2019-2025 | Jynarque |
| Glaxosmithkline, LLC. | $432.29 | 2021-2025 | Benlysta |
| Opko Pharmaceuticals, LLC | $421.91 | 2019-2024 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $402.07 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $326.48 | 2020-2024 | Acthar |
| Amgen INC. | $267.30 | 2019-2023 | Parsabiv, Tavneos |
| Calliditas Therapeutics US INC. | $259.71 | 2022-2025 | Tarpeyo |
| Horizon Therapeutics Plc | $250.90 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $181.19 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $145.66 | 2021-2023 | Lupkynis |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $125.00 | 2022 | |
| Veloxis Pharmaceuticals, INC. | $124.99 | 2022 | |
| Fresenius USA Marketing, INC. | $124.81 | 2019-2023 | Velphoro |
| Nxstage Medical, INC. | $100.32 | 2024 | |
| Ani Pharmaceuticals, INC. | $84.39 | 2025 | Purified Cortrophin Gel |
| Mallinckrodt Enterprises LLC | $80.01 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.97 | 2024 | Jardiance |
| Abbvie INC. | $63.11 | 2024-2025 | |
| Novo Nordisk INC | $56.38 | 2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $26.12 | 2021 | |
| Genentech USA, INC. | $26.03 | 2025 | Gazyva |
| Pfizer INC. | $24.34 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $23.35 | 2021 | |
| Apellis Pharmaceuticals, INC. | $20.61 | 2025 | Empaveli |
| Shield Therapeutics INC | $19.42 | 2025 | |
| Cumberland Pharmaceuticals, INC. | $18.67 | 2020 | |
| Boston Scientific Corporation | $17.50 | 2025 | Wavewriter Alpha Prime 16 |
| Daiichi Sankyo INC. | $15.50 | 2019 | |
| Xeris Pharmaceuticals, INC. | $14.73 | 2025 | Keveyis |
| Genzyme Corporation | $14.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashok Nath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.